SuperworthTeva Pharmaceutical Industries TEVA
- Market cap
- $45.9B
- PE
- 65.7×
- 5y median 25.8×
- Forward PE
- 14.1×
- 10y median 5.4×
- Price to sales
- 2.7×
- EV/EBIT
- 29.2×
- Revenue, 12 months
- $17.3B
- +4% on a year ago
- Net margin
- 4.1%
- Free cash flow yield
- 2.9%
Teva Pharmaceutical Industries trades at 65.7× trailing earnings, pricier than 95% of the last ten years. Revenue was $17.3B over the last twelve months, up 4% on a year earlier with a 4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.9B+7% | $4.5B+15% | $3.8B+4% | $4.2B+7% | $4.3B+13% | $4.2B−5% | $3.9B+2% | $4.2B+0% | $4.5B+3% | $4.7B+11% | $4B+2% | $4.1B−1% | |
| Cost of revenue | $2B+4% | $2B−3% | $2B−2% | $2.1B+3% | $2.2B+9% | $2.1B+3% | $2B−2% | $2.1B−3% | $2.2B−0% | $2.1B−3% | $2B−0% | $2B−4% |
| Gross profit | $1.9B+11% | $2.4B+36% | $1.8B+12% | $2B+13% | $2.1B+16% | $2.1B−12% | $1.9B+6% | $2.1B+4% | $2.3B+7% | $2.7B+25% | $2B+5% | $2.2B+2% |
| R&D | $253M+45% | $227M+8% | $242M+3% | $269M+12% | $240M−5% | $247M+9% | $247M+2% | $244M−9% | $256M+7% | $267M+8% | $222M−10% | $970M+298% |
| SG&A | $844M+3% | $902M+8% | $886M+5% | $939M+3% | $924M+10% | $952M+6% | $919M+4% | $959M+2% | $973M+5% | $1.1B+18% | $1B+9% | $1B+8% |
| $344M−18% | $756M | −$218M+1577% | −$5M−99% | −$51M | −$29M | $519M | $455M | $882M | $300M | $652M+26% | −$231M | |
| Pre-tax income | $64M−61% | $507M | −$467M+72% | −$246M−73% | −$324M | −$247M | $294M | $203M | $646M | $80M | $437M+49% | −$455M |
| −$12M | $41M−73% | −$52M+174% | $630M | $69M | $28M−32% | $74M | −$78M | $214M+210% | −$390M | $67M−10% | $121M | |
| Net income | $69M+23% | $463M | −$139M−37% | −$846M−3% | −$437M | −$217M | $214M | $282M | $433M | $480M | $369M+72% | −$576M |
| $0.06+20% | $0.41 | −$0.12−40% | −$0.75−4% | −$0.39 | −$0.19 | $0.18 | $0.24 | $0.37 | $0.41 | $0.31+72% | −$0.49 | |
| 1.1B+1% | 1.1B+1% | 1.1B+1% | 1.1B+1% | 1.1B−0% | 1.1B+1% | 1.2B+3% | 1.2B+3% | 1.2B+3% | 1.2B+3% | 1.2B+2% | 1.2B+0% |
EPS, diluted: Q4 FY17: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'. 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY17: not printed by the filing, worked out from its own lines. 5 periods, Q4 FY17 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY19 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $4.2B | $4.2B to $4.3B | $0.72 | $0.66 to $0.74 | 7 |
| Q4 FY26 | $4.1B | $4B to $4.3B | $0.74 | $0.64 to $0.90 | 7 |
| Q1 FY27 | $4B | $3.9B to $4.1B | $0.62 | $0.59 to $0.65 | 2 |
| Q2 FY27 | $4.2B | $4B to $4.3B | $0.70 | $0.68 to $0.74 | 2 |
| Q3 FY27 | $4.4B | $4.3B to $4.6B | $0.82 | $0.79 to $0.86 | 2 |
| Q4 FY27 | $4.4B | $4.3B to $4.6B | $0.85 | $0.82 to $0.89 | 5 |
Peers
Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TEVATeva Pharmaceutical Industries | $45.9B | 65.7× | 25.8× | 14.1× | 2.7× | +4% | 4.1% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| MDLNMedline | $44.8B | n/m | n/a | 23.2× | n/m | n/m | n/m |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| HUMHumana | $50.7B | 39.9× | 20.7× | 33.7× | 0.3× | +18% | 0.9% |
| EWEdwards Lifesciences | $51.3B | 51.2× | 40.3× | 28.3× | 7.9× | +15% | 15.4% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| BDXBecton, Dickinson and | $54.2B | 60.1× | 37.5× | 15.1× | 2.6× | +5% | 4.5% |
| Peer median | $45.4B | 50.1× | 37.5× | 28.7× | 7.0× | +13% | 10.7% |
Investors who own it
Investors we follow who held Teva Pharmaceutical Industries at the end of Jun 30, 2026, from their 13F filings.
- David EinhornGreenlight Capital2.5% of portfoliotrimmed
- Stanley DruckenmillerDuquesne Family Office0.5% of portfoliotrimmed
- Cathie WoodARK Investment Management0.0% of portfolioadded
- Ron BaronBaron Capital0.0% of portfolioadded
More on Teva Pharmaceutical Industries
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .